TTrialPathMatch Me to Trials
← Back to trials
RecruitingHodgkin Lymphoma in RemissionLeukemia in RemissionLymphoblastic Lymphoma

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Eligible age

All ages

Accepts

All genders

Locations

33 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.

Sponsor: Children's Oncology Group

You may qualify if…

  • ✓ Study Strata I, II, and III are closed for further patient entry as of March 31, 2021. The study remains open for existing medical record submission of Stratum IV
  • ✓ STRATUM I AND STRATUM II: LEUKEMIA AND LYMPHOMA SURVIVORS
  • ✓ Previously enrolled leukemia and lymphoma survivors, randomized to + or - DRZ on P9404, P9425, P9426, or DFCI 95-01 (high-risk patients only)
  • ✓ STRATUM I: Alive and in continuous first complete remission from their original cancer (leukemia/lymphoblastic lymphoma \[P9404, high-risk DFCI 95-01\] or Hodgkin lymphoma \[P9425/P9426\])
  • ✓ STRATUM I: Did not have progressive disease or induction failure requiring off-protocol therapy including hematopoietic cell transplantation
  • ✓ STRATUM I: Must not have been diagnosed with any subsequent malignancy that required additional cardiotoxic therapies (i.e., radiotherapy to the chest \[also includes fields directed towards the neck, upper abdomen, or spine\], or additional anthracyclines or anthraquinones); patients with history of subsequent malignancy that did not require such therapies remain eligible
  • ✓ STRATUM I: All patients and/or their parents or legal guardians must sign a written informed consent
  • ✓ STRATUM II: Among leukemia and lymphoma patients randomized to + or - DRZ on P9404, P9425, P9426, and DFCI 95-01 (high risk patients only) who have relapsed or have experienced a subsequent malignancy that precludes eligibility since their original diagnosis, the study committee will review the available data (both from Children's Oncology Group's \[COG?s\] Statistics and Data Center \[SDC\] and the participating institution) to determine if individual patients are to be selected for Stratum 2; in recognition that local institutions sometimes have more updated relapse/subsequent cancer data than SDC, in cases where local data is more updated, local data will be used preferentially; the study will petition the Institutional Review Board (IRB) specifically for a waiver of consent to include any relapse and subsequent cancer data obtained from existing records for analysis of the secondary aims; patients selected for Stratum 2 will be those for whom late relapse or subsequent cancer is reported but who lack clear confirmation in existing records (either at SDC or at the local institution)

Where it's recruiting

Alabama

Birmingham

Arizona

Phoenix · Tucson

Arkansas

Little Rock

California

Duarte · Madera · Oakland · Palo Alto …

Connecticut

New Haven

Florida

Fort Myers · Gainesville · Hollywood · Jacksonville …

Georgia

Atlanta

Hawaii

Honolulu

Illinois

Chicago · Oak Lawn · Peoria

Louisiana

New Orleans

Maine

Scarborough

Maryland

Baltimore

Source: ClinicalTrials.gov · NCT01790152 · last updated 2026-05-18

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Car · TrialPath